Sanofi (SNY) Net Income towards Common Stockholders (2009 - 2026)

Sanofi has reported Net Income towards Common Stockholders for 18 years, with the latest figure at -$7.6 billion in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 270.37% year-over-year to -$7.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.3 billion (down 133.19% YoY) and the FY2025 annual result came in at $9.1 billion, up 53.07% from the prior year.
• Net Income towards Common Stockholders slipped to -$7.6 billion in Q2 2026 per SNY's latest filing, from $1.9 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $10.1 billion in Q3 2025 and troughed at -$7.7 billion in Q4 2025.
• A 5-year average of $1.4 billion and a median of $1.9 billion in 2025 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 272.1% in 2025, down 1543.62% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $5.4 billion in 2022, then sank by 111.13% to -$597.1 million in 2023, then jumped by 189.3% to $533.2 million in 2024, then sank by 1543.62% to -$7.7 billion in 2025, then rose by 1.29% to -$7.6 billion in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.6 billion, $1.9 billion, and -$7.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.